Clinical Trials Logo

Clinical Trial Summary

The primary objective of this study is to evaluate safety and tolerability of DPK-060 2% ear drops compared to placebo for DPK-060 ear drops in patients with acute external otitis. The secondary objectives are to evaluate clinical cure and microbiological growth following treatment with DPK-060 2% ear drops compared to placebo for DPK-060 ear drops.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01447017
Study type Interventional
Source DermaGen AB
Contact
Status Completed
Phase Phase 2
Start date November 2011
Completion date November 2012

See also
  Status Clinical Trial Phase
Completed NCT02918773 - Pediatric Emergency Department Smartphone Otoscope Study (PED-Oto) N/A
Not yet recruiting NCT04636957 - A Phase III Study of Ciprofloxacin Plus Fluocinolone in Acute Otitis Externa (AOE) Phase 3
Completed NCT01535599 - Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa Phase 3
Completed NCT02801370 - Phase 3 Study of OTO-201 in Acute Otitis Externa Phase 3
Completed NCT00750633 - A Phase III Study of an Otic Formulation in Acute Otitis Externa Phase 3
Terminated NCT00945802 - FST-201 In The Treatment of Acute Otitis Externa Phase 3
Completed NCT03196973 - Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Acute Otitis Externa Phase 3
Recruiting NCT01584271 - Study of Ear Comfort Ear Drops to Treat AOE Cases Compared to DexOtic & Otidin(R) Phase 2
Completed NCT02216071 - Comparative Efficacy and Safety of Ciprofloxacin 0.3% and Dexamethasone 0.1% in Acute Otitis Externa Phase 3
Completed NCT00961675 - FST-201 in the Treatment of Acute Otitis Externa Phase 3
Completed NCT01535560 - Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa Phase 3